Roche nabs priority review for Eylea competitor; Italy's Angelini eyes CNS, rare disease startups with $35M Lumira fund
The teams at Roche and Genentech are off and running at the FDA, with regulators accepting a quick pitch for what would be the first …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
